ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · SPRY · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
8
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
ARS Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
SPRY insider buying and selling by quarter
SPRY insider selling · SPRY insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · SPRY ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
SPRY executive sell shares · SPRY board member insider trading · SPRY insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 13, 2025 | Dorsey Brian COO | Option | 21,828 | $14K | Form 4 |
| Nov 13, 2025 | Dorsey Brian COO | Sale | 21,828 | $190K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Option | 30,000 | $25K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 30,000 | $267K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 136,380 | $1.21M⚡ | Form 4 |
| Nov 12, 2025 | Shah Pratik Director | Gift | 250,000 | — | Form 4 |
| Nov 12, 2025 | Shah Pratik Director | Gift | 100,000 | — | Form 4 |
| Aug 21, 2025 | Lowenthal Richard E PRESIDENT AND CEO · Director | Sale | 50,000 | $724K | Form 4 |
| Aug 21, 2025 | Scott Kathleen D. CFO | Option | 12,500 | $19K | Form 4 |
| Aug 21, 2025 | Scott Kathleen D. CFO | Sale | 12,500 | $188K | Form 4 |
| Aug 19, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale | 12,344 | $173K | Form 4 |
| Aug 20, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale | 37,656 | $531K | Form 4 |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Option | 15,000 | $23K | Form 4 |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Sale | 15,000 | $255K | Form 4 |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Option | 15,000 | $23K | Form 4 |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Sale | 15,000 | $240K | Form 4 |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Option | 100,000 | $558K | Form 4 |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Sale | 102,969 | $1.45M⚡ | Form 4 |
| May 20, 2025 | SAUNDERS BRENT L Director | Option | 120,000 | $121K | Form 4 |
| May 20, 2025 | SAUNDERS BRENT L Director | Sale | 120,000 | $1.71M⚡ | Form 4 |
| May 20, 2025 | Scott Kathleen D. CFO | Option | 50,000 | $75K | Form 4 |
| May 20, 2025 | Scott Kathleen D. CFO | Sale | 50,000 | $705K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Option | 27,493 | $133K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Option | 22,509 | $109K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Sale | 50,002 | $615K | Form 4 |
Chakma Justin
Chief Business Officer
Date
Nov 12
Shares
30,000
Price
$0.84
Value
$25K
Chakma Justin
Chief Business Officer
Date
Nov 12
Shares
30,000
Price
$8.91
Value
$267K
Chakma Justin
Chief Business Officer
Date
Nov 12
Shares
136,380
Price
$8.86
Value
$1.21M ⚡
Lowenthal Richard E
PRESIDENT AND CEO · Director
Date
Aug 21
Shares
50,000
Price
$14.49
Value
$724K
Tanimoto Sarina
CHIEF MEDICAL OFFICER
Date
Aug 19
Shares
12,344
Price
$14.03
Value
$173K
Tanimoto Sarina
CHIEF MEDICAL OFFICER
Date
Aug 20
Shares
37,656
Price
$14.09
Value
$531K
Karas Eric
Chief Commercial Officer
Date
Jul 1
Shares
15,000
Price
$1.50
Value
$23K
Karas Eric
Chief Commercial Officer
Date
Jul 1
Shares
15,000
Price
$16.99
Value
$255K
Karas Eric
Chief Commercial Officer
Date
Jun 18
Shares
15,000
Price
$1.50
Value
$23K
Karas Eric
Chief Commercial Officer
Date
Jun 18
Shares
15,000
Price
$16.00
Value
$240K
Fitzpatrick Alexander A
Chief Legal Officer
Date
May 20
Shares
100,000
Price
$5.58
Value
$558K
Fitzpatrick Alexander A
Chief Legal Officer
Date
May 20
Shares
102,969
Price
$14.10
Value
$1.45M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About SPRY insider trading
SPRY insider trades
ARS Pharmaceuticals, Inc. (SPRY) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Karas Eric (Chief Commercial Officer), Chakma Justin (Chief Business Officer), Dorsey Brian (COO). Over the past 12 months, 5 insiders have filed transactions with the SEC. SPRY insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For ARS Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
SPRY insider trading · 5 questionsThe insiders of ARS Pharmaceuticals, Inc. (SPRY) include executives and directors such as Karas Eric (Chief Commercial Officer), Chakma Justin (Chief Business Officer), Dorsey Brian (COO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026